News >

Genomic, Transcriptomic Profiling Lays Groundwork for Personalization in RCC

Caroline Seymour
Published: Tuesday, Jan 29, 2019

A. Ari Hakimi, MD

A. Ari Hakimi, MD

RNA-based analyses of prospectively-collected tumor specimens from patients with metastatic renal cell carcinoma (mRCC) in the phase III COMPARZ trial revealed 4 molecular subgroups, of which a high angiogenesis expression and a low macrophage infiltrate were indicative of response to frontline TKI therapy.1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication